Burande Clara F, Heuzé Mélina L, Lamsoul Isabelle, Monsarrat Bernard, Uttenweiler-Joseph Sandrine, Lutz Pierre G
Institut de Pharmacologie et de Biologie Structurale (IPBS) CNRS 205 Route de Narbonne and IPBS, Université Paul Sabatier Université de Toulouse, Toulouse France.
Mol Cell Proteomics. 2009 Jul;8(7):1719-27. doi: 10.1074/mcp.M800410-MCP200. Epub 2009 Apr 17.
The ubiquitin-proteasome system is a central mechanism for controlled proteolysis that regulates numerous cellular processes in eukaryotes. As such, defects in this system can contribute to disease pathogenesis. In this pathway, E3 ubiquitin ligases provide platforms for binding specific substrates, thereby coordinating their ubiquitylation and subsequent degradation by the proteasome. Despite the identification of many E3 ubiquitin ligases, the identities of their specific substrates are still largely unresolved. The ankyrin repeat-containing protein with a suppressor of cytokine signaling box 2 (ASB2) gene that we initially identified as a retinoic acid-response gene in acute promyelocytic leukemia cells encodes the specificity subunit of an E3 ubiquitin ligase complex that is involved in hematopoietic cell differentiation. We have recently identified filamin A and filamin B as the first ASB2 targets and shown that ASB2 triggers ubiquitylation and proteasome-mediated degradation of these proteins. Here a global quantitative proteomics strategy is provided to identify substrates of E3 ubiquitin ligases targeted to proteasomal degradation. Indeed we used label-free methods for quantifying proteins identified by shotgun proteomics in extracts of cells expressing wild-type ASB2 or an E3 ubiquitin ligase-defective mutant of ASB2 under the control of an inducible promoter. Measurements of spectral count and mass spectrometric signal intensity demonstrated a drastic decrease of filamin A and filamin B in myeloid leukemia cells expressing wild-type ASB2 compared with cells expressing an E3 ubiquitin ligase-defective mutant of ASB2. Altogether we provide an original strategy that enables identification of E3 ubiquitin ligase substrates that have to be degraded.
泛素-蛋白酶体系统是一种用于控制蛋白质水解的核心机制,它调节真核生物中的众多细胞过程。因此,该系统的缺陷可能导致疾病的发病机制。在这一途径中,E3泛素连接酶为结合特定底物提供平台,从而协调其泛素化以及随后被蛋白酶体降解的过程。尽管已经鉴定出许多E3泛素连接酶,但其特定底物的身份在很大程度上仍未明确。我们最初在急性早幼粒细胞白血病细胞中鉴定为视黄酸反应基因的含锚蛋白重复序列和细胞因子信号抑制盒2(ASB2)基因,编码一种参与造血细胞分化的E3泛素连接酶复合物的特异性亚基。我们最近已将细丝蛋白A和细丝蛋白B鉴定为ASB2的首批靶点,并表明ASB2触发这些蛋白质的泛素化以及蛋白酶体介导的降解。本文提供了一种全局定量蛋白质组学策略,以鉴定靶向蛋白酶体降解的E3泛素连接酶的底物。实际上,我们使用无标记方法对通过鸟枪法蛋白质组学在诱导型启动子控制下表达野生型ASB2或ASB2的E3泛素连接酶缺陷型突变体的细胞提取物中鉴定出的蛋白质进行定量。光谱计数和质谱信号强度的测量表明,与表达ASB2的E'3泛素连接酶缺陷型突变体的细胞相比,表达野生型ASB2的髓系白血病细胞中细丝蛋白A和细丝蛋白B急剧减少。总之,我们提供了一种原创策略,能够鉴定必须被降解的E3泛素连接酶底物。